[A21-104] Pembrolizumab (Hodgkin lymphoma) - Addendum to Commission A21-35
Last updated 16.09.2021
Commission awarded on 10.08.2021 by the Federal Joint Committee (G-BA).
Adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant or following at least two prior therapies when autologous stem cell transplant is not a treatment option
Unchanged after addendum:
- Adults for whom brentuximab vedotin is the suitable therapy according to physician’s choice: hint of non-quantifiable added benefit.
- Adults for whom brentuximab vedotin is not the suitable therapy according to physician’s choice: added benefit not proven.
- Children and adolescents aged 3 years and older: added benefit not proven.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A21-35||Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2021-09-16 A G-BA decision was published.